Global Information
회사소개 | 문의 | 비교리스트

세계의 POC(Point of Care) 분자진단 시장 : 검사장소별(OTC, PoC), 용도별(감염증, 종양), 최종 용도별, 기술별, 부문별 예측(2019-2024년)

Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location (OTC, PoC), By Application (Infectious Diseases, Oncology), By End Use, By Technology, And Segment Forecasts, 2019 - 2024

리서치사 Grand View Research, Inc.
발행일 2019년 05월 상품 코드 361251
페이지 정보 영문 150 Pages
가격
US $ 5,950 ₩ 7,181,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 8,388,000 Printable PDF (5-User License)
US $ 8,950 ₩ 10,802,000 Printable PDF (Enterprise License)


세계의 POC(Point of Care) 분자진단 시장 : 검사장소별(OTC, PoC), 용도별(감염증, 종양), 최종 용도별, 기술별, 부문별 예측(2019-2024년) Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location (OTC, PoC), By Application (Infectious Diseases, Oncology), By End Use, By Technology, And Segment Forecasts, 2019 - 2024
발행일 : 2019년 05월 페이지 정보 : 영문 150 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 POC(Point-of-Care) 분자진단(Molecular Diagnostics) 시장은 2019-2024년간 14.4%의 CAGR로 추이하며, 2024년까지 38억 6,000만 달러 규모의 시장으로 성장할 것으로 예측됩니다. 고정밀도이며 신속하게 임상 현장에서 시행 가능한 분자진단 검사의 소형화에 대한 지속적 연구개발이 이 시장의 주요 성장 촉진요인입니다.

세계의 POC(Point-of-Care) 분자진단 시장을 조사했으며, 시장 개요, 용도·기술·검사장소·최종 용도·지역별 시장 규모의 추이와 예측, 시장 기회, 시장 성장요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화와 범위
  • 시장의 정의
  • 정보 조달
  • 정보 분석
  • 시장 형성과 데이터 가시화
  • 정보 검증과 공개

제2장 개요

  • 시장 전망

제3장 산업 전망

  • 침투 및 성장 전망 지도제작
  • 시장 동향 분석
  • 시장 역학
    • 시장 성장요인
    • 시장 억제요인
  • 시장 기회 분석
  • Porter의 산업 분석
  • 규제 환경
  • SWOT 분석
  • 시장 점유율 분석
  • 경쟁 구도
    • 전략적 프레임워크
    • 기업 분류

제4장 POC(Point-of-Care) 분자진단 시장 : 용도별

  • 시장 점유율 분석 : 용도별
  • 감염증
  • 종양
  • 혈액
  • 산전 진단
  • 내분비
  • 기타

제5장 POC(Point-of-Care) 분자진단 시장 : 기술별

  • 시장 점유율 분석 : 기술별
  • PCR
  • 유전자 시퀀싱
  • 하이브리다이제이션
  • 마이크로어레이

제6장 POC(Point-of-Care) 분자진단 시장 : 검사장소별

  • 시장 점유율 분석 : 검사장소별
  • OTC
  • PoC

제7장 POC(Point-of-Care) 분자진단 시장 : 최종 용도별

  • 시장 점유율 분석 : 최종 용도별
  • 분산형 랩
  • 병원
  • 홈케어
  • 생활 지원 의료시설
  • 기타

제8장 POC(Point-of-Care) 분자진단 시장 : 지역별

  • 시장 점유율 분석 : 지역별
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
  • 아시아태평양
    • 일본
    • 중국
  • 중남미
    • 브라질
  • 중동·아프리카
    • 남아프리카공화국

제9장 경쟁 환경

  • Abbott Laboratories
  • Alere Inc(Abbott)
  • Bayer Healthcare
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Danaher Corporation
  • BioMerieux
  • Dako
  • Abaxis Inc.
  • OraSure Technologies Inc.
  • Nipro Diagnostics
  • Qiagen
  • Nova Biomedical
KSA 19.06.20

List of Tables

  • TABLE 1 Point-of-care Molecular Diagnostics market - Industry Snapshot & Key Buying Criteria, 2013 - 2024
  • TABLE 2 Global Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 3 Global Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 4 Global Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 5 Global Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 6 Global Point-of-care Molecular Diagnostics market, by region, 2013 - 2024 (USD Million)
  • TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
  • TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
  • TABLE 9 North America Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 10 North America Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 11 North America Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 12 North America Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 13 U.S. Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 14 U.S. Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 15 U.S. Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 16 U.S. Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 17 Canada Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 18 Canada Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 19 Canada Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 20 Canada Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 21 Europe Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 22 Europe Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 23 Europe Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 24 Europe Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 25 Germany Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 26 Germany Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 27 Germany Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 28 Germany Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 29 U.K. Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 30 U.K. Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 31 U.K. Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 32 U.K. Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 33 Asia Pacific Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 34 Asia Pacific Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 35 Asia Pacific Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 36 Asia Pacific Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 37 Japan Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 38 Japan Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 39 Japan Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 40 Japan Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 41 China Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 42 China Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 43 China Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 44 China Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 45 Latin America Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 46 Latin America Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 47 Latin America Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 48 Latin America Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 49 Brazil Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 50 Brazil Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 51 Brazil Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 52 Brazil Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 53 MEA Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 54 MEA Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 55 MEA Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 56 MEA Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • TABLE 57 South Africa Point-of-care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 58 South Africa Point-of-care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 59 South Africa Point-of-care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 60 South Africa Point-of-care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1 Point-of-care Molecular Diagnostics market segmentation
  • FIG. 2 Global Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 3 Point-of-care Molecular Diagnostics market dynamics
  • FIG. 4 Key opportunities prioritized, 2018
  • FIG. 5 Point-of-care Molecular Diagnostics market - Porter's Analysis
  • FIG. 6 Point-of-care Molecular Diagnostics market - PESTEL analysis
  • FIG. 7 Point-of-care Molecular Diagnostics revenue share, by application, 2018 & 2024
  • FIG. 8 POC MDx Infectious Diseases market, 2013 - 2024 (USD Million)
  • FIG. 9 POC MDx Oncology market, 2013 - 2024 (USD Million)
  • FIG. 10 POC MDx Hematology market, 2013 - 2024 (USD Million)
  • FIG. 11 POC MDx Prenatal Testing market, 2013 - 2024 (USD Million)
  • FIG. 12 POC MDx Endocrinology market, 2013 - 2024 (USD Million)
  • FIG. 13 POC MDx Other Applications market, 2013 - 2024 (USD Million)
  • FIG. 14 Point-of-care Molecular Diagnostics revenue share, by technology, 2018 & 2024
  • FIG. 15 POC MDx PCR-based market, 2013 - 2024 (USD Million)
  • FIG. 16 POC MDx Genetic Sequencing-based market, 2013 - 2024 (USD Million)
  • FIG. 17 POC MDx Hybridization-based market, 2013 - 2024 (USD Million)
  • FIG. 18 POC MDx Microarray-based market, 2013 - 2024 (USD Million)
  • FIG. 19 Point-of-care Molecular Diagnostics revenue share, by test location, 2018 & 2024
  • FIG. 20 POC MDx over-the-counter market, 2013 - 2024 (USD Million)
  • FIG. 21 POC MDx point-of-care market, 2013 - 2024 (USD Million)
  • FIG. 22 Point-of-care Molecular Diagnostics revenue share, by end-use, 2018 & 2024
  • FIG. 23 POC MDx Decentralized Labs market, 2013 - 2024 (USD Million)
  • FIG. 24 POC MDx Hospitals market, 2013 - 2024 (USD Million)
  • FIG. 25 POC MDx Home-care market, 2013 - 2024 (USD Million)
  • FIG. 26 POC MDx Assisted Living Healthcare Facilities market, 2013 - 2024 (USD Million)
  • FIG. 27 POC MDx Other uses market, 2013 - 2024 (USD Million)
  • FIG. 28 Point-of-care Molecular Diagnostics revenue share, by region, 2018 & 2024
  • FIG. 29 North America Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 30 U.S. Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 31 Canada Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 32 Europe Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 33 Germany Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 34 U.K. Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 35 Asia Pacific Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 36 Japan Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 37 China Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 38 Latin America Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 39 Brazil Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 40 MEA Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 41 South Africa Point-of-care Molecular Diagnostics market, 2013 - 2024 (USD Million)

The global point-of-care molecular diagnostics market size is anticipated to reach USD 3.86 billion by 2024 expanding at a CAGR of 14.4%, according to a new report by Grand View Research, Inc. Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy and lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.

Growing demand for CLIA tests that are, by definition, portable and safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings, is expected to drive demand in the market over the forecast period. Ongoing research and development is continually supported and funded by a number of major international entities including the governments of developed countries.

Furthermore, a growing portfolio of point-of-care testing capabilities that, had initially been focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties. Consequently, POC and molecular diagnosis tests are available and/or are under development for cardiology monitoring, oncology testing, and hematology testing.

Recent advances in the development of microfluidics and genetic sequencing instrumentation pave the way for development of cost-effective, highly accurate and rapid testing platforms, which are able to be used as true POC systems. This is a key factor that significantly contributes towards the favorably funded, high growth potential environment prevalent in the PoC molecular diagnostics market.

Further key findings from the study suggest:

  • Application of POC MDx tests for infectious diseases accounted for over 45% of market revenue in 2018 due to the presence of many major market entities with an extensive product portfolio
  • Growing burden of infectious diseases in both developing and developed countries is another factor responsible for the dominance of this segment
  • PCR-based POC tests is the largest revenue generating segment of the market in 2018. Widespread usage of PCR-based techniques for molecular diagnosis and commercialization of POC real time PCR products have provided ample opportunities for segment growth
  • North America was the largest region and accounted for 43.5% of the global revenue share due to the presence of technologically advanced medical framework, high R&D investments by governments and private organizations for the development of POC MDx tests

Key companies in the market include: Johnson & Johnson; Danaher Corp.; Cepheid, Inc.; Bio-Rad Laboratories, Inc.; bioMerieux; Becton, Dickinson and Company; F. Hoffmann-La Roche AG; Bayer HealthCare Pharmaceuticals LLC ; Alere, Inc.; (Abbott), and Abbott Laboratories.

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Market segmentation & scope
  • 1.2 Market definition
  • 1.3 Information procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources & third party perspectives
    • 1.3.4 Primary research
  • 1.4 Information analysis
    • 1.4.1 Data analysis models
  • 1.5 Market formulation & data visualization
  • 1.6 Data validation & publishing

Chapter 2. Executive Summary

  • 2.1 PoC Molecular Diagnostics Market Outlook, 2013-2024

Chapter 3. Industry Outlook

  • 3.1 Penetration & Growth Prospects Mapping
  • 3.2 Trend analysis
    • 3.2.1 Application trends
    • 3.2.2 Product trends
    • 3.2.3 End-use trends
    • 3.2.4 Regional trends
  • 3.3 PoC Molecular Diagnostics- Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Introduction of CLIA waived tests
      • 3.3.1.2 Rise in funding from government & private institutions
      • 3.3.1.3 Growing demand for home healthcare and introduction of novel products
      • 3.3.1.4 Growing geriatric population base
      • 3.3.1.5 Growing prevalence of target diseases
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 High procedure costs
      • 3.3.2.2 Ambiguous regulatory framework
  • 3.4 Opportunity Analysis
  • 3.5 Industry Analysis - Porter's
    • 3.5.1 Supplier power - Medium
    • 3.5.2 Buyer power - High
    • 3.5.3 Substitution threat - Low
    • 3.5.4 New entrants threat - Low
  • 3.6 Regulatory Landscape: PoC Molecular Diagnostics - SWOT by PEST Analysis
    • 3.6.1 Political landscape
    • 3.6.2 Economic landscape
    • 3.6.3 Social landscape
    • 3.6.4 Technology landscape
  • 3.7 Company Market Share Analysis
  • 3.8 Competitive Landscape
    • 3.8.1 Strategy framework
    • 3.8.2 Company categorization
      • 3.8.2.1 New entrants
      • 3.8.2.2 Mature players & leaders

Chapter 4. Point-of-Care Molecular Diagnostics Market, by Application Outlook

  • 4.1 PoC Molecular Diagnostics Market Share by Application Outlook, 2013 to 2024
  • 4.2 Infectious Diseases, 2013 to 2024
    • 4.2.1 Infectious diseases market revenue (USD Million), by North America
    • 4.2.2 Infectious diseases market revenue (USD Million), by Europe
    • 4.2.3 Infectious diseases market revenue (USD Million), by Asia Pacific
    • 4.2.4 Infectious diseases market revenue (USD Million), by Latin America
    • 4.2.5 Infectious diseases market revenue (USD Million), by Middle-East & Africa
  • 4.3 Oncology, 2013 to 2024
    • 4.3.1 Oncology market revenue (USD Million), by North America
    • 4.3.2 Oncology market revenue (USD Million), by Europe
    • 4.3.3 Oncology market revenue (USD Million), by Asia Pacific
    • 4.3.4 Oncology market revenue (USD Million), by Latin America
    • 4.3.5 Oncology market revenue (USD Million), by Middle-East & Africa
  • 4.4 Hematology, 2013 to 2024
    • 4.4.1 Hematology market revenue (USD Million), by North America
    • 4.4.2 Hematology market revenue (USD Million), by Europe
    • 4.4.3 Hematology market revenue (USD Million), by Asia Pacific
    • 4.4.4 Hematology market revenue (USD Million), by Latin America
    • 4.4.5 Hematology market revenue (USD Million), by Middle-East & Africa
  • 4.5 Prenatal Testing, 2013 to 2024
    • 4.5.1 Prenatal Testing market revenue (USD Million), by North America
    • 4.5.2 Prenatal Testing market revenue (USD Million), by Europe
    • 4.5.3 Prenatal Testing market revenue (USD Million), by Asia Pacific
    • 4.5.4 Prenatal Testing market revenue (USD Million), by Latin America
    • 4.5.5 Prenatal Testing market revenue (USD Million), by Middle-East & Africa
  • 4.6 Endocrinology, 2013 to 2024
    • 4.6.1 Endocrinology market revenue (USD Million), by North America
    • 4.6.2 Endocrinology market revenue (USD Million), by Europe
    • 4.6.3 Endocrinology market revenue (USD Million), by Asia Pacific
    • 4.6.4 Endocrinology market revenue (USD Million), by Latin America
    • 4.6.5 Endocrinology market revenue (USD Million), by Middle-East & Africa
  • 4.7 Other Applications, 2013 to 2024
    • 4.7.1 Other applications market revenue (USD Million), by North America
    • 4.7.2 Other applications market revenue (USD Million), by Europe
    • 4.7.3 Other applications market revenue (USD Million), by Asia Pacific
    • 4.7.4 Other applications market revenue (USD Million), by Latin America
    • 4.7.5 Other applications market revenue (USD Million), by Middle-East & Africa

Chapter 5. Point-of-care Molecular Diagnostics Outlook, by Technology Outlook

  • 5.1 PoC Molecular Diagnostics Market Share by Technology Outlook, 2013 to 2024
  • 5.2 PCR-based, 2013 to 2024
    • 5.2.1 PCR based market revenue (USD Million), by North America
    • 5.2.2 PCR based market revenue (USD Million), by Europe
    • 5.2.3 PCR based market revenue (USD Million), by Asia Pacific
    • 5.2.4 PCR based market revenue (USD Million), by Latin America
    • 5.2.5 PCR based market revenue (USD Million), by Middle-East & Africa
  • 5.3 Genetic Sequencing-based, 2013 to 2024
    • 5.3.1 Genetic sequencing based market revenue (USD Million), by North America
    • 5.3.2 Genetic sequencing based market revenue (USD Million), by Europe
    • 5.3.3 Genetic sequencing based market revenue (USD Million), by Asia Pacific
    • 5.3.4 Genetic sequencing based market revenue (USD Million), by Latin America
    • 5.3.5 Genetic sequencing based market revenue (USD Million), by Middle-East & Africa
  • 5.4 Hybridization-based, 2013 to 2024
    • 5.4.1 Hybridization based market revenue (USD Million), by North America
    • 5.4.2 Hybridization based market revenue (USD Million), by Europe
    • 5.4.3 Hybridization based market revenue (USD Million), by Asia Pacific
    • 5.4.4 Hybridization based market revenue (USD Million), by Latin America
    • 5.4.5 Hybridization based market revenue (USD Million), by Middle-East & Africa
  • 5.5 Microarray-based, 2013 to 2024
    • 5.5.1 Microarray based market revenue (USD Million), by North America
    • 5.5.2 Microarray based market revenue (USD Million), by Europe
    • 5.5.3 Microarray based market revenue (USD Million), by Asia Pacific
    • 5.5.4 Microarray based market revenue (USD Million), by Latin America
    • 5.5.5 Microarray based market revenue (USD Million), by Middle-East & Africa

Chapter 6. Point-of-care Molecular Diagnostics Outlook, by Test Location

  • 6.1 PoC Molecular Diagnostics Market Share by Test Location Outlook, 2013 to 2024
  • 6.2 OTC (Over-the-counter), 2013 to 2024
    • 6.2.1 OTC market revenue (USD Million), by North America
    • 6.2.2 OTC market revenue (USD Million), by Europe
    • 6.2.3 OTC market revenue (USD Million), by Asia Pacific
    • 6.2.4 OTC market revenue (USD Million), by Latin America
    • 6.2.5 OTC market revenue (USD Million), by Middle-East & Africa
  • 6.3 POC (Point-of-care), 2013 to 2024
    • 6.3.1 PoC market revenue (USD Million), by North America
    • 6.3.2 PoC market revenue (USD Million), by Europe
    • 6.3.3 PoC market revenue (USD Million), by Asia Pacific
    • 6.3.4 PoC market revenue (USD Million), by Latin America
    • 6.3.5 PoC market revenue (USD Million), by Middle-East & Africa

Chapter 7. Point-of-care Molecular Diagnostics Outlook, By End-use

  • 7.1 PoC Molecular Diagnostics Market Share by Technology Outlook, 2013 to 2024
  • 7.2 Decentralized Labs, 2013 to 2024
    • 7.2.1 Decentralized labs market revenue (USD Million), by North America
    • 7.2.2 Decentralized labs market revenue (USD Million), by Europe
    • 7.2.3 Decentralized labs market revenue (USD Million), by Asia Pacific
    • 7.2.4 Decentralized labs market revenue (USD Million), by Latin America
    • 7.2.5 Decentralized labs market revenue (USD Million), by Middle-East & Africa
  • 7.3 Hospitals, 2013 to 2024
    • 7.3.1 Hospitals market revenue (USD Million), by North America
    • 7.3.2 Hospitals market revenue (USD Million), by Europe
    • 7.3.3 Hospitals market revenue (USD Million), by Asia Pacific
    • 7.3.4 Hospitals market revenue (USD Million), by Latin America
    • 7.3.5 Hospitals market revenue (USD Million), by Middle-East & Africa
  • 7.4 Homecare, 2013 to 2024
    • 7.4.1 Homecare market revenue (USD Million), by North America
    • 7.4.2 Homecare market revenue (USD Million), by Europe
    • 7.4.3 Homecare market revenue (USD Million), by Asia Pacific
    • 7.4.4 Homecare market revenue (USD Million), by Latin America
    • 7.4.5 Homecare market revenue (USD Million), by Middle-East & Africa
  • 7.5 Assisted Living Healthcare Facilities, 2013 to 2024
    • 7.5.1 Assisted living healthcare facilities market revenue (USD Million), by North America
    • 7.5.2 Assisted living healthcare facilities market revenue (USD Million), by Europe
    • 7.5.3 Assisted living healthcare facilities market revenue (USD Million), by Asia Pacific
    • 7.5.4 Assisted living healthcare facilities market revenue (USD Million), by Latin America
    • 7.5.5 Assisted living healthcare facilities market revenue (USD Million), by Middle-East & Africa
  • 7.6 Other Uses, 2013 to 2024
    • 7.6.1 Other uses market revenue (USD Million), by North America
    • 7.6.2 Other uses based market revenue (USD Million), by Europe
    • 7.6.3 Other uses based market revenue (USD Million), by Asia Pacific
    • 7.6.4 Other uses based market revenue (USD Million), by Latin America
    • 7.6.5 Other uses based market revenue (USD Million), by Middle-East & Africa

Chapter 8. Point-of-care Molecular Diagnostics Regional Outlook

  • 8.1 PoC Molecular Diagnostics Market share by region, 2013 to 2024
  • 8.2 North America
    • 8.2.1 PoC molecular diagnostics market revenue, (USD Million), by U.S.
    • 8.2.2 PoC molecular diagnostics market revenue, (USD Million), by Canada
    • 8.2.3 U.S.
      • 8.2.3.1 U.S. Point-of-care Molecular Diagnostics market, by application outlook
      • 8.2.3.2 U.S. Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.2.3.3 U.S. Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.2.3.4 U.S. Point-of-care Molecular Diagnostics market, by end-use outlook
    • 8.2.4 Canada
      • 8.2.4.1 Canada Point-of-care Molecular Diagnostics market, by application outlook
      • 8.2.4.2 Canada Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.2.4.3 Canada Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.2.4.4 Canada Point-of-care Molecular Diagnostics market, by end-use outlook
  • 8.3 Europe
    • 8.3.1 PoC molecular diagnostics market revenue, (USD Million), by U.S.
    • 8.3.2 PoC molecular diagnostics market revenue, (USD Million), by Canada
    • 8.3.3 Germany
      • 8.3.3.1 Germany Point-of-care Molecular Diagnostics market, by application outlook
      • 8.3.3.2 Germany Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.3.3.3 Germany Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.3.3.4 Germany Point-of-care Molecular Diagnostics market, by end-use outlook
    • 8.3.4 U.K.
      • 8.3.4.1 U.K. Point-of-care Molecular Diagnostics market, by application outlook
      • 8.3.4.2 U.K. Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.3.4.3 U.K. Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.3.4.4 U.K. Point-of-care Molecular Diagnostics market, by end-use outlook
  • 8.4 Asia Pacific
    • 8.4.1 PoC molecular diagnostics market revenue, (USD Million), by U.S.
    • 8.4.2 PoC molecular diagnostics market revenue, (USD Million), by Canada
    • 8.4.3 Japan
      • 8.4.3.1 Japan Point-of-care Molecular Diagnostics market, by application outlook
      • 8.4.3.2 Japan Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.4.3.3 Japan Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.4.3.4 Japan Point-of-care Molecular Diagnostics market, by end-use outlook
    • 8.4.4 China
      • 8.4.4.1 China Point-of-care Molecular Diagnostics market, by application outlook
      • 8.4.4.2 China Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.4.4.3 China Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.4.4.4 China Point-of-care Molecular Diagnostics market, by end-use outlook
  • 8.5 Latin America
    • 8.5.1 PoC molecular diagnostics market revenue, (USD Million), by U.S.
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil Point-of-care Molecular Diagnostics market, by application outlook
      • 8.5.2.2 Brazil Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.5.2.3 Brazil Point-of-care Molecular Diagnostics market, by test location outlook
      • 8.5.2.4 Brazil Point-of-care Molecular Diagnostics market, by end-use outlook
  • 8.6 MEA
    • 8.6.1 PoC molecular diagnostics market revenue, (USD Million), by U.S.
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa Point-of-care Molecular Diagnostics market, by application outlook
      • 8.6.2.2 South Africa Point-of-care Molecular Diagnostics market, by technology outlook
      • 8.6.2.3 South Africa Point-of-care Molecular Diagnostics market, by test location outlook
      • South Africa Point-of-care Molecular Diagnostics market, by end-use outlook

Chapter 9. Competitive Landscape

  • 9.1 Abbott Laboratories
    • 9.1.1 Company overview
    • 9.1.2 Financial performance
    • 9.1.3 Product benchmarking
    • 9.1.4 Strategic development
  • 9.2 Alere Inc (Abbott)
    • 9.2.1 Company overview
    • 9.2.2 Financial performance
    • 9.2.3 Product benchmarking
    • 9.2.4 Strategic development
  • 9.3 Bayer Healthcare
    • 9.3.1 Company overview
    • 9.3.2 Financial performance
    • 9.3.3 Product benchmarking
    • 9.3.4 Strategic development
  • 9.4 Roche Diagnostics
    • 9.4.1 Company overview
    • 9.4.2 Financial performance
    • 9.4.3 Product benchmarking
    • 9.4.4 Strategic development
  • 9.5 Bio-Rad Laboratories
    • 9.5.1 Company overview
    • 9.5.2 Financial performance
    • 9.5.3 Product benchmarking
    • 9.5.4 Strategic development
  • 9.6 Danaher Corporation
    • 9.6.1 Company overview
    • 9.6.2 Financial performance
    • 9.6.3 Product benchmarking
    • 9.6.4 Strategic development
  • 9.7 BioMerieux
    • 9.7.1 Company overview
    • 9.7.2 Financial performance
    • 9.7.3 Product benchmarking
    • 9.7.4 Strategic development
  • 9.8 Dako
    • 9.8.1 Company overview
    • 9.8.2 Financial performance
    • 9.8.3 Product benchmarking
    • 9.8.4 Strategic development
  • 9.9 Abaxis Inc.
    • 9.9.1 Company overview
    • 9.9.2 Financial performance
    • 9.9.3 Product benchmarking
    • 9.9.4 Strategic development
  • 9.10 OraSure Technologies Inc.
    • 9.10.1 Company overview
    • 9.10.2 Financial performance
    • 9.10.3 Product benchmarking
    • 9.10.4 Strategic development
  • 9.11 Nipro Diagnostics
    • 9.11.1 Company overview
    • 9.11.2 Financial performance
    • 9.11.3 Product benchmarking
    • 9.11.4 Strategic development
  • 9.12 Qiagen
    • 9.12.1 Company overview
    • 9.12.2 Financial performance
    • 9.12.3 Product benchmarking
    • 9.12.4 Strategic development
  • 9.13 Nova Biomedical
    • 9.13.1 Company overview
    • 9.13.2 Financial performance
    • 9.13.3 Product benchmarking
    • 9.13.4 Strategic development
Back to Top
전화 문의
F A Q